168澳洲幸运5官网结果记录体彩 幸运五分彩直播结果 在线查询澳大利亚五结果体彩记录图 2026澳5彩票+澳洲幸运5体彩官方网站 News
bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control. With this strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions that will support the growing advanced therapy market and improve patient outcomes worldwide.
Swipe to discover more
-
bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of its immunoassay endocrinology offer for equine health, consisting of VIDAS® Equine INSULIN and VIDAS® Equine ACTH. -
"Always consider sepsis in the context of infection."
Patient associations across the globe are actively engaged in promoting this critical message to both healthcare professionals and the broader public. We met with Dr Rafael Moraes from ILAS, Melissa Mead from The UK Sepsis Trust and Thomas Heymann from Sepsis Alliance to learn more about their actions. -
Food Safety Trends Building Momentum into 2026
As 2026 begins, bioMérieux proudly continues our tradition of looking into the next twelve months and analyzing how key food safety trends will influence the food supply chain and our partners’ operations. The three identified trends for 2026 will continue to develop and inform food safety and quality standards — standards that we at bioMérieux are proud to help pioneer and contribute to.
澳洲5幸运官网结果168预测记录 Enabling Decision-Making 168体彩幸运澳洲5正规官方网站
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19